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Hyperbaric oxygen therapy (HBOT) is defined as a treatment in which a patient intermittently breathes 100%
oxygen while the treatment chamber is pressurized to a pressure greater than sea level (1.0 atmosphere absolute,
ATA). In China, for nearly 50 years, HBOT has been used as a primary or adjuvant therapy to treat a variety of
diseases. This article mainly reviewed the indications and contraindications of HBOT, as well as the status of clinical
and experimental HBOT research in China. At the same time, there is a brief introduction of hyperbaric oxygen
preconditioning (HBO-PC) in China.
Keywords: Hyperbaric oxygen therapy, China, Indications and contraindications, Clinical and basic researchBackground
In 1887, Valenzuela successfully pioneered the applica-
tion of 2.0 Mpa of pure oxygen to treat clinical disease
[1], the use of hyperbaric oxygen therapy (HBOT) for
clinical practice has a history of more than 100 years
from then on. The hyperbaric oxygen chamber was first
used in China by the Fujian Medical University Union
Hospital in 1964 [2]. Since then, HBOT has experienced
nearly 50 years of rapid development in China. The basic
principle behind HBOT is to increase the amount of
oxygen dissolved in the blood by administering it at a
pressure greater than sea level (1.0 atmosphere absolute,
ATA). In this way, the pressure gradient will distribute
O2 throughout the body and maintain tissue in a hyper-
oxygenated state [3]. Currently, there are more than
5000 hyperbaric oxygen chambers in China [4]. This
number is the highest in the world, and significantly
contributes to the amount of global HBOT research [4].
In China, HBOT has been adapted to treat a wide variety
of diseases. This paper reviewed the current clinical appli-
cations of HBOT (including indications and contraindica-
tions) and both clinical and basic HBOT research in
China in recent years to provide theoretical evidence for a
rational clinical use of HBOT.HBOT in clinical practice
HBOT use in China began in the 1960s and developed
rapidly after political reform and opening-up. As a result* Correspondence: chengoumei01@aliyun.com
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unless otherwise stated.of this expansion of the practice of HBOT, a platform was
urgently needed to develop standards of practice. To ad-
dress this concern, the Chinese Medical Association
(CMA), which was established in 1915 as the institution
for the development of medical science and technology in
China, organized a branch for hyperbaric oxygen medicine
in 1992. Since then, the branch of hyperbaric oxygen
medicine of the CMA has held annual academic confer-
ences. These conferences provide a platform for academic
exchange for the majority of HBO therapists in China.
The internet communication platform, China Hyperbaric
Oxygen (CHO) was created in 2000 by QingLe Liu, the dir-
ector of the Second Military Medical University Medical
Center of Hyperbaric Oxygen. Through those platforms,
HBOT has gradually moved toward standardization.
HBOT is commonly used on patients with ischemic
hypoxic damage. With the wide clinical application of
hyperbaric oxygen therapy, the Chinese Professional
Committee of Hyperbaric Oxygen drafted the indication
and contraindication standards of practice in 1982 in an
effort to reduce the number of patients experiencing toxic
side effects of HBOT. The CMA revised the indication
and contraindication standards in 2004 and 2013; the
2004 version is widely used in clinical practice, followed
by the indications and contraindications of 2004.The indications of HBOT
Indications refer to the scope and standards for the suit-
able use of HBOT. A few countries other than China
have developed their own standards for HBOT. In the
United States, in 1989, the Undersea and Hyperbaricis is an Open Access article distributed under the terms of the Creative
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HBOT use that include 13 diseases [5]. In 2014, the
number of indications increased to 17 (Table 1). In 2004,
the European Committee for Hyperbaric Medicine
(ECHM) divided their recommended indications into 4
categories: 8 highly recommended indications, 10 rec-
ommended indications, 9 controversial indications,and
13 other indications that include 40 other diseases [6].
Compared to the United States and Europe, the number
of hyperbaric oxygen indications approved in China is
relatively high. The indications of HBOT were initially
released in China in 1982. With the practice and recogni-
tion of HBOT, the CMA revised the recommended indica-
tions in 2004 [4] to include 12 emergency indications and
48 non-emergency indications.
Emergency indications are diseases where HBOT should
be administered as soon as possible. The following are emer-
gency indications: (1) acute carbon monoxide poisoning and
other harmful gas poisoning; (2) gas gangrene, tetanus and
other anaerobic bacteria infections; (3) decompression sick-
ness; (4) air embolism syndrome; (5) after cardiopulmonary
resuscitation (CPR) due to a variety of risks for acute brain
dysfunction; (6) aid in the treatment of shock; (7) brain
edema; (8) pulmonary edema (except cardiac pulmonary
edema); (9) crush syndrome; (10) limb (finger, toe) and the
blood supply after skin transplantation; (11) drug and chem-
ical poisoning;(12) acute ischemia anoxic encephalopathy.
Additionally, the following non-emergency indica-
tions are approved for use: (1) carbon monoxide poison-
ing or other toxic encephalopathy; (2) sudden deafness;
(3) ischemic cerebrovascular disease (cerebral arterio-
sclerosis, transient ischemic attack, cerebral thrombosis,
cerebral infarction); (4) craniocerebral injury (concussion,Table 1 HBO Indications of UHMS
Air or gas embolism; Diabetically derived illness, such


















syndrome, and other acute
traumatic ischemias;
Osteomyelitis (refractory);
Decompression sickness; Delayed radiation injury
(soft tissue and bony necrosis);
Enhancement of healing in
selected problem wounds;
Skin grafts and flaps (compromised);
Thermal burns.cerebral contusion of intracranial hematoma removal
surgery, brain stem injury); (5) cerebral hemorrhage re-
covery; (6) poor healing fractures; (7) central serous
retinal inflammation; (8) vegetative state; (9) plateau
adaptation insufficiency syndrome; (10) peripheral
nerve injury; (11) intracranial benign tumor surgery;
(12) periodontal disease; (13) viral encephalitis; (14) fa-
cial paralysis; (15) osteomyelitis; (16) aseptic osteo-
necrosis; (17) cerebral palsy; (18) fetal developmental
delays; (19) diabetes and diabetic foot; (20) coronary
atherosclerotic heart disease (angina and myocardial
infarction); (21) rapidity arrhythmia (atrial fibrillation,
premature beat, tachycardia); (22) myocarditis; (23)
peripheral vascular disease, vasculitis, e.g., Raynaud’s,
deep vein thrombosis, etc.; (24) vertigo; (25) chronic
skin ulcer (arterial blood supply obstacles, venous con-
gestion, bedsore); (26) spinal cord injury; (27) peptic
ulcer; (28) ulcerative colitis; (29) infectious hepatitis
(use the special chamber of infectious disease); (30)
burns; (31) frostbite; (32) plastic surgery; (33) skin
grafting; (34) sports injuries; (35) radioactive damage
(bone and soft tissue, cystitis, etc.); (36) malignant tu-
mors (with radiotherapy or chemotherapy); (37) otic
nerve injury; (38) fatigue syndrome; (39) angioneurotic
headache; (40) pustular; (41)psoriasis; (42) pityriasisro-
sea; (43) multiple sclerosis; (44) acute Guillain-Barre
syndrome; (45) recurrent oral ulcer; (46) paralytic
ileus; (47) bronchial asthma; and (48) acute respiratory
distress syndrome.
The current HBOT indications and contraindications
were released at the 22nd academic meeting held in
Qingdao in 2013 and approved on the 1st of November
2013. The new indications include diseases that were
directly or indirectly caused by hypoxia and/or ischemia
or a series of conditions that are related to hypoxia and/
or ischemia in the evolution of the disease process. In
comparison to the 2004 edition, the new indications
broaden the use of HBOT.
The contraindications of HBOT
Contraindications refer to the diseases or predicaments
where the use of HBOT is inappropriate, possibly leading
to adverse consequences, including body injury and even
death. The CMA published the contraindications of
hyperbaric oxygen treatment in 2004, which includes 4
absolute contraindications and 10 relative contraindications.
Absolute contraindications are those where HBOT is
prohibited if the patient is accompanied with following:
(1) untreated pneumothorax, untreated pneumomedias-
tinum; (2) pulmonary bulla; (3) active hemorrhage and
hemorrhagic disease; or (4) the formation of tuberculous
cavity and hemoptysis.
Relative contraindications refer to the conditions
where the use of HBOT in patients is cautioned and
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or complications. Thus, HBOT should be used with cau-
tion if a patient has one of the following conditions: (1)
severe upper respiratory tract infection; (2) severe em-
physema; (3) bronchiectasis disease; (4) sinus infection;
(5) aII degree atrioventricular block; (6) high blood pres-
sure (>160/100 mmHg); (7) bradycardia (<50 times/min);
(8) untreated malignant tumor; (9) retinal detachment;
and (10) the early stage of pregnancy (3 months).
In 2013, new contraindications for HBOT were re-
leased by CMA. The new contraindications include ab-
solute contraindications and relative contraindications.
The only absolute contraindication is tension pneumo-
thorax without treatment. The relative contraindications
are as follows: (1) intraventricular external drainage; (2)
fracture of the skull base with cerebrospinal fluid leak-
age; (3) birth weight < 2000 g in premature and low birth
weight infants; (4) serious infection of the upper respira-
tory tract; (5) high blood pressure (SBP > 180 mmHg,
DBP > 110 mmHg); and (6) patients with chronic obstruct-
ive pulmonary disease with CO2 retention. Compared to
the previous contraindications, the current contraindica-
tions are less strict. For example, regarding blood pressure,
the 2004 standard is > 160/100 mmHg, but the new stand-
ard is > 180/110 mmHg. Still, adverse effects can occur
even when following stricter HBOTcontraindications.
Clinical and basic research of HBOT in China
HBOT has been widely adopted since its introduction in
China. With the wide application of HBOT in clinical
settings, a substantial amount of research relevant to
HBOT has been published. According to the Chinese
National Knowledge Infrastructure (CNKI), there are
13,357 articles related to hyperbaric oxygen (before Aug
2013). Using “hyperbaric oxygen” and “China” as key
words, 218 articles appeared in PubMed (before Aug,













Figure 1 The number of published articles on hyperbaric oxygen in Csuggests that HBOT in China is still in the development
stage. The amount of published HBOT research has been
increasing every year for nearly a decade (2003–2013).
However in 2012, there was a decline in HBOT research
(Figure 1).
Here, we summarized HBOT research in China using
original research articles found in PubMed that focus on
both clinical and basic research.Clinical research
A lot of clinical research on HBOT has been published
recently. Within the last ten years (2004–2013), 9
randomized controlled trials (RCTs) have been pub-
lished. The patients used in those studies had a variety
of disorders, including neurologic, otolaryngologic,
stomatologic, dermatologic, and urologic disorders.
The cohorts for those trials ranged in size from 24 to
236. The Jadad – Bechara scale is often used to assess
the quality of a clinical trial study. The Jadad scale
(Table 2), which was developed by Columbia doctor,
Alejandro Jadad – Bechara, is sometimes referred to as
the Jadad score or the Oxford scoring system and is the
most widely used rating scale for clinical trial research [7].
According to the Jadad scale, a score between 1 and 3 in-
dicates a low quality study, where as a score between 4
and 7 indicates a high quality study [8]. The 9 RCTs found
within the last ten years are summarized and graded for
their quality in Table 3 [9-15].
The HBO RCTs in China were generally of low
quality (scores ranged from 1–2). Thus, the curative
effect of HBOT cannot be determined from these
studies. For a more rigorous test of the curative ef-
fects of HBOT, future experiments should sea stricter
research design that includes a randomized, double
blind, and multicenter approach, as well as a large
sample.008 2009 2010 2011 2012 2013
Year
hina.








1 not described 1 numbers and reasons
are described
Allocation concealment 0 numbers and reasons
are not described
3 central randomization Efficacy of randomization




1 not described or
inadequate
1 balance of pre-treatment
variables
Investigator blindness 1 balance of pre-treatment
variables mentioned but not in
tabular form
2 identical placebo tables
or similar
0 no information report
1 inadequate or not
described
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Although the therapeutic effect of HBOT has been con-
firmed in the clinic, the mechanism is not fully under-
stood. The principle strategy of HBOT is to increase
the oxygen content of the blood, improve blood oxygen
partial pressure, improveblood oxygen dispersion and
increase the tissue oxygen “effective diffusion distance”
while constricting blood vessels and promoting the
establishment of collateral circulation. HBOT can affect
many physiological processes. In different disease states,
HBOT is associated with decreased apoptotic cell death,









Cao H 2013 Jun 30/30 2
Chen TL 2012 Oct 30/30 2
Peng Z 2012 Nov 68 2
Tang XP 2011 Nov 60/60 2
Shao Y 2012 Mar 18/18 2
Tang X 2011 Mar 116/116 2
Jiang W 2011 Jan 48/35 2
Liu Y 2010 Oct 60/60 1
Yuan JB 2011 Sep 12/12 1and the activation of stem cells and other mechanisms. I
will mainly describe the next four mechanisms, and most
of the related diseases are mainly involved in nervous
system.The inhibition of cell apoptosis
HBOT inhibits cell apoptosis by regulating apoptosis-
related proteins in a variety of pathological models. HBOT
can reduce the secretion of caspase-3, which is critical for
apoptosis induced by proteases [16] in different rat models
of ischemia. These models include brain ischemia-hypoxia
in neonatal rats [17] and cerebral ischemia-reperfusion in-
jury in adult rats [18]. In addition, similar anti-apoptotic
effects have been reported in models of myocardial infarc-
tion [19]. B-cell lymphoma 2 (Bcl-2) is an inhibitor of the
apoptosis protein, Bax, which is a Bcl-2-related protein
that pro-apoptotic. The ratio of Bcl-2/Bax is up regulated
by HBOT and inhibits cell apoptosis in a rat model of
myocardial infarction [19]. In addition, Thioredoxin
Reductase(TrxR), an antioxidant, also has an antiapop-
totic effect that can involve HBOT [20]. For example,
HBOT is beneficial for the improvement of anxiety-like
behavior and cognitive impairments in stressed rats; this
effect might be associated with the inhibition of neuronal
apoptosis via up regulation of TrxR [21].The reduction of inflammation
HBOT can reduce inflammation by reducing the release of
inflammatory mediators. Such inflammatory mediators in-
clude the lymphokine (IL) family and tumor necrosis fac-
tor (TNF). For example, HBOT attenuated inflammation
via the reduction ofIL-1, IL-6, IL-8, and IL-10expression
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reperfusion injury in rats [25]. Besides, HBOT can also
reduce inflammation by reducing the incidence of mem-
brane cofactor protein-1(MCP-1), keratinocyte-derived
chemokine (KC), and IFN-gamma-inducible protein 10
(IP-10) [26]. In addition, the anti-inflammatory effect of
HBOT may be related to the inhibition of specific sig-
naling pathways. HBOT may mitigate secondary injury
to the spinal cord(SC) by inhibiting inflammatory re-
sponses induced by the TLR2/NF-кB and the iNOS
mRNA-iNOS-NO signaling pathways, thereby promoting
functional recovery in spinal cord injury in rats [27,28].The balance of oxygen free radicals
Oxygen free radicals are a product of metabolic pro-
cesses of the body. Because oxygen free radicals gener-
ally exist in the body, their production and scavenging
are normally in a dynamic equilibrium. The appropriate
levels of oxygen free radicals can facilitate tissue metab-
olism and cell detoxification, but excessive oxygen free
radicals will damage the body [4]. In theory, HBO can
increase oxygen free radicals. HBOT initiated soon after
acute transient cerebral ischemia in rats increases mito-
chondrial free radical levels but also increases the activ-
ity of superoxide dismutase (SOD), which is important
for scavenging free radicals. Thus, the net effect is an in-
crease in oxygen and a reduction in oxygen free radicals,
which then protects the body [29,30].Activation of neural stem cells
A stem cell is a type of undifferentiated immature cell
that has the potential for proliferation, migration and
differentiation into all types of tissue cells; this is bene-
ficial for the recovery of damaged tissue. Neurogenesis
plays an important role in the recovery of neurological
function. HBOT activation of stem cells may represent
a viable new research direction. Wang XL found that in
newborn rats with hypoxic ischemic brain damage
(HIBD), HBOT could promote migration and differen-
tiation of endogenous neural stem cells (NSCs) in the
subventricular zone (SVZ) into cerebral cortex neurons
[31], but its mechanism still need further research.
HBOT can promote neurogenesis in the piriform cor-
tex(Pir) of adult rats with vascular dementia(VD) [32].
HBOT has a different effect at different pressures and
different exposure times. HBOT at 2 ATA for 60 mi-
nutes produces the highest levels of differentiation of
NSCs into neurons in cerebral cortices of newborn rats
[33]. Current research on the effects of HBOT on
neurogenesis mainly involves NSC activation, but research
using other types of stem cells remains to be explored in
the future.Hyperbaric oxygen preconditioning (HBO-PC)
HBO pretreatment can have a protective effect that allevi-
ates the secondary damage after some stimulation; this is
known as hyperbaric oxygen preconditioning (HBO-PC).
In a clinical trial of forty-nine elective on-pump or off-
pump coronary artery bypass graft surgery patients, Li Y
found that HBO-PC improved the outcome of patients
undergoing on-pump coronary artery bypass graft surgery.
The on-pump group had a reduced length of stay in the
intensive care unit and a decreased use of inotropic drugs
[34]. Although the mechanism of precondition is not fully
understood, animal research suggests that HBOT may
mitigate surgery-induced cognitive impairment [35] and
reduce ischemia-reperfusion (IR) injury of the rat brain [36].
HBO-PC can reduce the number of apoptotic cells and
promote nerve functional recovery [37,38]. The protection
mechanism may involve reduction of systemic and hippo-
campal proinflammatory cytokines, reduction of COX-2
(an inflammatory medium) [39], suppression of caspase-3 ac-
tivity [35], or up regulation of HSP32 expression (Heat Shock
Protein 32, a protein that inhibits normal cell death) [40].Summary
HBOT in China has a wide range of indications, involv-
ing nearly every system of the human body. However,
contraindications are relatively limited. Although the use
of HBOT in China for the clinical treatment of various
diseases has been widely studied, the quality of these
clinic trials is generally low due to a small sample size
and high heterogeneity between studies. Research with a
stricter design that includes, random trials, blind experi-
mentation, multiple centers, and large samples are
needed for further confirmation. The mechanism of
HBOT has been examined in animal model studies,
which mainly report improvement of microcirculation,
decrease in apoptotic cells, reduction of inflammation,
adjustment of the balance of oxygen free radicals, and the
activation of stem cells. Still, the mechanism of HBOT in
the human body is not fully understood. Further study
using advanced non-invasive techniques, such as Positron
Emission Tomography Computed Tomography (PET-CT)
and functional Magnetic Resonance Imaging (fMRI) may
help discover additional mechanisms. HBO-PC can reduce
injury to the body in some cases, and its prospects for
clinical application as well as the in-depth study of its
mechanism will be of broad interest.
The number of published articles on hyperbaric oxy-
gen is increasing year by year, but in 2012, there was a
decline (From PubMed).
The clinical RCTs of HBO in China are generally of
low quality (quality score ranged from 1–2). Definitive
curative effects of HBOT cannot be concluded from
these studies.
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